Рейтинговое агентство GCR повысило кредитный рейтинг фармацевтической компании MeCure Industries до стабильного уровня BBB

Business Follow Us on GoogleJuly 6, 2026 by Joseph Eshanokpe MeCure Industries gets GCR’s Stable BBB outlook The leading rating agency in Africa, Global Credit Rating Co. (Pty) Limited (GCR), has given MeCure Industries Plc a long-term issuer rating at BBB(NG) and short-term issuer rating at A2(NG) for the first half of 2026. This move revises the company’s long-term outlook to Stable. The rating agency said their decision was supported by improvements in MeCure’s competitive position, sound earnings, expansion, product innovation, and wider market penetration. MeCure Industries, the pharmaceutical giant, was incorporated in Nigeria on March 16, 2005 and re-registered on October 28, 2022. Its revenue in 2024 was N46,026,565,000 and profit after tax hit N2,328,675, according to its annual and financial report signed by its Chairman, Samir Udani and Co-CEO, Mrs Dukor Ndidi GCR noted MeCure’s large product portfolio of over 140 formulations across five therapeutics, extensive distribution network, and its good relationships with suppliers and technical partners. READ ALSO: DPO under fire In 2025, GCR assigned MeCure assigned MeCure’s national long-term and short-term rating issuer of BBB(NG) and A3(NG), with positive outlook, while in 2024, it was BBB(NG) and A3, Stable, the reason this new upgrade excites MeCure Industries’ Chief Financial Officer, Ifedamola F. Oluwasegun. During the period under review, MeCure also received Halal certification, a testament to the company’s commitment to quality, compliance, and broader consumer accessibility. The certification, experts said, means that the company’s products have been reviewed to meet Halal requirements. Also, it gives consumers more confidence that the medicines are okay, and provide transparency, product integrity, and manufacturing discipline. Also, MeCure has also launched Fluconazole Capsules and EBU Suspension. Fluconazole Capsules add to the company’s antifungal offering, while EBU Suspension, an ibuprofen oral suspension, strengthens MeCure’s paediatric and family care range. The launch reflects the company’s continued focus on affordable,and local medicines. In the second half of the year, the company pledged to focus on boosting local quality manufacturing, improving access to quality medicines, expanding its product pipeline, and delivering sustainable value to shareholders.